Prolong Pharmaceuticals Names Industry Veteran Glenn Kazo President

SOUTH PLAINFIELD, N.J., Sept. 28 /PRNewswire/ -- Prolong Pharmaceuticals today announced that industry veteran Glenn Kazo has assumed the title of President. Mr. Kazo has been consulting in various capacities with Prolong since 2007. He succeeds Prolong founder Dr. Abraham Abuchowski, who remains Chief Executive Officer.

"I have known Glenn for more than thirty years," said Dr. Abuchowski, who co-founded Enzon Pharmaceuticals in 1981 with Mr. Kazo. "I feel he is one of the greatest strategic minds in the biopharmaceutical world today, with a long history of successful experience behind him guiding small companies and startups. Through his consulting input and counsel, Glenn has already played a central role in Prolong's development, and as we move into the next phase of product development he will assume the major operational responsibilities for the company," said Dr. Abuchowski.

At Enzon, Kazo headed the steering committee for the blockbuster cancer drug PEG-Interferon. As Vice President of Sales and Marketing he built and managed a significant business development and licensing group and launched the company's first two drugs, Adagen® and Oncaspar® . Following Enzon, Kazo joined Focal, Inc., now a division of Genzyme, and helped take that company public. He later served as US General Manager and a member of the Board of Directors for the UK-listed public company XTL Biopharmaceuticals, and subsequently as Chief Business Office for Activbiotics a private VC backed anti-infective company.  Kazo has been responsible for raising over $300M in capital from international investors, including a leading role in three successful IPOs.

About Prolong Pharmaceuticals

Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing biopharmaceutical products targeting the treatment of anemia resulting from an oxygen deficiency. First founded in 2002 as a research company Prolong is focused on sickle cell anemia, diabetic ischemia, and several trauma indications. The company's senior management team includes inventors of the most successful drug delivery technology in pharmaceutical history, PEGylation, now responsible for more than $30 billion in drug sales worldwide. For more information visit: www.prolongpharmaceuticals.com.

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.